Heparin-induced thrombocytopenia in paediatric patients – a review of the literature and a new case treated with danaparoid sodium

1999 ◽  
Vol 158 (S3) ◽  
pp. S130-S133 ◽  
Author(s):  
Oliver Ranze ◽  
Petra Ranze ◽  
Harry N. Magnani ◽  
Andreas Greinacher
VASA ◽  
2020 ◽  
pp. 1-6 ◽  
Author(s):  
Marina Di Pilla ◽  
Stefano Barco ◽  
Clara Sacco ◽  
Giovanni Barosi ◽  
Corrado Lodigiani

Summary: A 49-year-old man was diagnosed with pre-fibrotic myelofibrosis after acute left lower-limb ischemia requiring amputation and portal vein thrombosis. After surgery he developed heparin-induced thrombocytopenia (HIT) with venous thromboembolism, successfully treated with argatroban followed by dabigatran. Our systematic review of the literature supports the use of dabigatran for suspected HIT.


1998 ◽  
Vol 79 (01) ◽  
pp. 1-7 ◽  
Author(s):  
Theodore Warkentin ◽  
Beng Chong ◽  
Andreas Greinacher

SummaryHeparin-induced thrombocytopenia (HIT) is a drug-induced, immunoglobulin-mediated thrombocytopenic disorder that is important for at least three reasons. First, it is a relatively common drug-induced immunohematologic adverse reaction. Second, it is frequently complicated by life- and limb-threatening thrombotic complications. And third, there remains uncertainty about the optimal treatment approach for these patients. Recently, there has emerged increasing consensus on such important issues as the frequency, pathogenesis, and diagnostic testing, which we will summarize here. Further, a greater appreciation of the activation of the coagulation pathways in this syndrome indicate a rationale to treatment approaches that emphasize thrombin inhibition (eg. danaparoid sodium; hirudin and its analogues).


2015 ◽  
Vol 4 (2) ◽  
pp. 73 ◽  
Author(s):  
Fariborz Farsad ◽  
Farzaneh Foroughinia ◽  
Kheirollah Gholami ◽  
Somayeh Ahmadi

2003 ◽  
Vol 9 (1) ◽  
pp. 25-32 ◽  
Author(s):  
Joachim F. Schenk ◽  
Gerhard Pindur ◽  
Bernhard Stephan ◽  
Stephan Mürsdorf ◽  
Friedrich Mertzlufft ◽  
...  

2017 ◽  
Vol 07 (12) ◽  
pp. 400-407
Author(s):  
Malcolm R. DeBaun ◽  
Michael A. Spinner ◽  
Michael D. Genualdi ◽  
Caroline Berube ◽  
Derek F. Amanatullah

2021 ◽  
Vol 7 (3) ◽  
pp. 71-77
Author(s):  
I. D. Shapovalov ◽  
V. E. Makarchenko ◽  
O. Yu. Kartina ◽  
T. L. Belousova

The heparin-induced thrombocytopenia is a severe, potentially life-threatening complication of heparinotherpapia associated with thrombosis, develops as a result of antibody-mediated platelet activation. In the context of the SARS CoV-2 pandemic, the frequency of use of heparin in clinical practice has significantly increased, as a result of which the doctors have become more likely to face this complication. The article presents a review of the literature, describes the pathogenesis, modern algorithms for diagnosis and treatment, demonstrates a clinical case of heparin-induced thrombocytopenia in a patient with the SARS CoV-2, and discusses the features of diagnosis and treatment of this complication in a naval hospital.


Sign in / Sign up

Export Citation Format

Share Document